54 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus Collaboration https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx?source=iedfolrf0000001 Apr 30, 2020 - The combined effort of these two companies marks one of the largest manufacturing collaborations on the planet toward a coronavirus vaccine.
SNY vs. NVO: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/900968/sny-vs-nvo-which-stock-is-the-better-value-option?cid=CS-ZC--tale_of_the_tape|yseop_template_3-900968 Apr 30, 2020 - SNY vs. NVO: Which Stock Is the Better Value Option?
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine http://www.zacks.com/stock/news/899331/healthcare-etfs-to-gain-on-progress-in-coronavirus-vaccine?cid=CS-ZC-FT-etf_news_and_commentary-899331 Apr 29, 2020 - The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax http://www.zacks.com/stock/news/897526/the-zacks-analyst-blog-highlights-moderna-johnson-johnson-sanofi-and-novavax?cid=CS-ZC-FT-press_releases-897526 Apr 29, 2020 - The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
Is a Beat in Store for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/898431/is-a-beat-in-store-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-898431 Apr 29, 2020 - Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Should Value Investors Buy Sanofi (SNY) Stock? http://www.zacks.com/stock/news/894160/should-value-investors-buy-sanofi-sny-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-894160 Apr 28, 2020 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Stocks to Benefit From Race to Develop Coronavirus Vaccines http://www.zacks.com/stock/news/894002/3-stocks-to-benefit-from-race-to-develop-coronavirus-vaccines?cid=CS-ZC-FT-analyst_blog|investment_ideas-894002 Apr 28, 2020 - Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.
Positive Cancer Trial Results Offset a COVID-19 Flop for Regeneron and Sanofi https://www.fool.com/investing/2020/04/27/positive-cancer-trial-results-offset-a-covid-19-fl.aspx?source=iedfolrf0000001 Apr 27, 2020 - The companies shared good news about lung cancer patients treated with Libtayo, and bad news about a potential treatment for COVID-19.
Regeneron, Sanofi Say Kevzara Will Now Only Be Tested in Sickest COVID-19 Patients https://www.fool.com/investing/2020/04/27/regeneron-sanofi-say-kevzara-will-now-only-be-test.aspx?source=iedfolrf0000001 Apr 27, 2020 - The companies are halting clinical studies of the drug in those with severe cases of COVID-19 and focusing only on critical patients.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS http://www.zacks.com/stock/news/891794/big-drug-stock-q1-earnings-due-on-apr-28-mrk-pfe-and-nvs?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-891794 Apr 27, 2020 - Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.

Pages: 123456

Page 1>